BAJAJ BROKING
Cipla's Goa facility underwent a US FDA inspection, resulting in six Form 483 observations. The company aims to promptly address these within the set timeframe to resolve regulatory concerns, focusing on the areas of potential non-compliance with standards.
Cipla Ltd, a prominent pharmaceutical company, underwent an inspection by the US Food and Drug Administration (USFDA) at its manufacturing facility in Goa, spanning from June 10 to June 21, 2024. The outcome of this inspection included the issuance of six inspection observations documented in Form 483.
Form 483 is a significant regulatory document issued by the US FDA inspectors post-inspection. It lists observations made regarding deviations from current Good Manufacturing Practices (cGMP) at the inspected facility.
These observations are communicated to the company during a closing conference but do not constitute a final decision on compliance.
Explore: Cipla Share Price
Despite the observations, Cipla expressed its commitment to collaborating closely with the US FDA to address the identified issues comprehensively within the stipulated time frame. The company emphasised its dedication to resolving these matters promptly to maintain regulatory compliance and uphold quality standards.
Cipla, known for its global presence and focus on sustainable growth, operates in key markets including India, South Africa, North America, and other regulated and emerging markets.
The company's recent financial performance underscores its robust position in the pharmaceutical industry. Cipla reported a 79% increase in consolidated net profit to ₹939.04 crore and a 10% rise in revenue from operations to ₹6,163 crore in Q4 FY24 compared to Q4 FY23.
Disclaimer: Investments in the securities market are subject to market risk, read all related documents carefully before investing.
This content is for educational purposes only. Securities quoted are exemplary and not recommendatory.
For All Disclaimers Click Here: https://bit.ly/3Tcsfuc
Share this article:
Share Market Today | Gift Nifty Signals 100-Point Gap Down, Nifty to Consolidate
06 Sep, 2024 | 4 Min. read
KEC International Secures ₹1,423 Cr Transmission Line Order in Saudi Arabia
06 Sep, 2024 | 1 Min. read
Ashoka Buildcon’s Viva Highways Monetises Pune Land for ₹453 Crore
06 Sep, 2024 | 2 Min. read
Peak Partners To Sell 11% Stake in Indigo Paints via Block Deal
06 Sep, 2024 | 2 Min. read
US Initial Jobless Claims Drop to 227,000 in August.
06 Sep, 2024 | 1 Min. read
Commodities Market Today | WTI Crude Steady at $69.18, Gold Rises 0.8% to $2,546
06 Sep, 2024 | 1 Min. read
Gold Rate Today | Gold Rises 0.8% to $2,546, Silver Gains 2% to $29.14
06 Sep, 2024 | 2 Min. read
Vodafone Idea Share Price Falls 11% After Goldman Sachs Report
06 Sep, 2024 | 1 Min. read
Suzlon Energy Share Price Rises After Corporate Office Sale
06 Sep, 2024 | 1 Min. read
Why is the Stock Market Down Today? Key Factors Explained
06 Sep, 2024 | 1 Min. read
Sona BLW Precision Forgings Plans ₹2,400 Crore QIP at ₹675-700 per Share
05 Sep, 2024 | 1 Min. read
Commodities Market Today | Crude Oil Drops, Brent Hits Low; Gold and Silver Rise
05 Sep, 2024 | 1 Min. read
Analysis to Become a Pro Investor
28 Dec, 2023 | 4 Min. read
Women In Real Estate Investing (Investree)
28 Dec, 2023 | 5 Min. read
How To Check Prudent Corporate Advisory IPO Allotment Status
27 Dec, 2023 | 3 Min. read
How To Boost Credit Score? – Steps to Improve Creditworthiness
27 Dec, 2023 | 4 Min. read
Advantages and Disadvantages of Opening Multiple Demat Accounts
26 Dec, 2023 | 4 Min. read
7th CPC LTC: Leave Travel Concession Rules for Central Government Employees
26 Dec, 2023 | 4 Min. read
7th Pay Commission: House Building Advance (HBA) Interest Rate FY 2023-24
26 Dec, 2023 | 5 Min. read
The Future of Trading: Exploring Bajaj Broking’s Demat Features
26 Dec, 2023 | 6 Min. read
7th Central Pay Commission Cpc Fitment Table
23 Dec, 2023 | 7 Min. read
Level up your stock market experience: Download the Bajaj Broking App for effortless investing and trading